Abstract 1397P
Background
Antibody-drug conjugates (ADCs) may extend targeted therapy to patients (pts) whose tumors express an antigen regardless of the presence of a driver mutation. Telisotuzumab vedotin (ABBV-399), a first-in-class MET (or c-Met)-directed ADC, had promising monotherapy anticancer activity in previously treated pts with MET-overexpressing (OE), non-squamous EGFR wild type NSCLC (Camidge et al. JCO. 2022;40:16 suppl, 9016). Characterization of MET OE NSCLC, a novel biomarker-defined therapeutically relevant subgroup, is thus warranted. MET OE was evaluated in a real-world cohort and co-associated with mRNA expression, MET gene amplification (METamp) and mutations, and outcomes to understand prognosis of MET OE NSCLC.
Methods
The cohort comprised treated pts with stage IV NSCLC seeking care at City of Hope National Medical Center in ≥2016 and had tissue adequate for MET immunohistochemistry (IHC). MET OE was determined using anti-MET clone SP44 IHC assay (Roche Tissue Diagnostics; positive if ≥25% cells at 3+ intensity). MET FISH, RNAseq, and whole exome sequencing were conducted. Clinical data were extracted from electronic health records, and unadjusted hazard ratios from 1L treatment initiation until death or censoring were calculated. Pts receiving targeted therapy in 1L were excluded.
Results
84 pts were included; 77% had samples taken prior to metastatic spread. 21 (25%) were MET OE positive. MET OE was not associated with history of smoking. METamp was found in 5/69 tumors evaluated (9%); of these, 2 were MET OE. Only 2 pts had MET mutations; neither were exon 14 skipping and one was MET OE. MET mRNA, evaluated in 58 cases, was 4-fold higher in MET OE NSCLC vs not OE. 1L regimens used were chemotherapy (52.4%), chemotherapy + immune checkpoint inhibitor (ICI; 26.2%), or ICI (21.4%). The unadjusted hazard ratio for death in pts with MET OE NSCLC vs not OE was 2.04 (95% CI: 1.02, 4.10).
Conclusions
Pts with MET OE NSCLC had worse prognosis compared with those without MET OE, when treated with standard of care including ICI. Given the development of MET-directed ADCs, MET OE (distinct from METamp) may be a future target for characterization and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Funding
AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and approval of this abstract. No honoraria or payments were made for authorship.
Disclosure
J. Bar: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Bayer, BMS, Causalis, Eisai, MSD, Novartis, Roche, Takeda; Financial Interests, Personal, Research Funding: Immunai, OncoHost, MSD, AstraZeneca. M.H. Cai: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. Y.C. Choi: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Baijal: Financial Interests, Personal, Other, Honoraria: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Foundation One, Gilead, GSK, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi, and Takeda. W. Zhao: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Liede: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Raskin: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. A. Vasilopoulos: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. M. Li: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. L. Roberts-Rapp: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc.. F. Jiang: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. C. Ratajczak: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. S. Lu: Financial Interests, Personal, Other, Grants or contracts: AstraZeneca, Hutchmed, Bristol Myers Squibb, Hengrui Medicine, BeiGene, Roche, and Hansoh; Financial Interests, Personal, Other, Honoraria for lectures or presentations: AstraZeneca and Hansoh; Financial Interests, Personal, Other, Advisor and consultant: AstraZeneca, Pfizer, Hutchmed, Zai Lab, GenomiCare Biotechnology (Shanghai), Yuhan, Menarini, InventisBio Co., and Roche; Financial Interests, Personal, Other, Data safety monitoring board or advisory board participation: AstraZeneca, Roche, and Mirati Therapeutics. P.J. Ansell: Financial Interests, Personal, Stocks/Shares, Employee and may own stock: AbbVie Inc. D.R. Camidge: Financial Interests, Personal, Advisory Role: AbbVie (steering committee), Amgen, Anheart, Apollomics (SRC), AstraZeneca (SRC/SC), AstraZeneca/Daiichi (ILD adjudication committee), BeiGene (IDMC, DSMB), Bio-Thera (DSMB), Blueprint, Daiichi Sankyo (ILD adjudication committee), Dizal, Elevation (SRC), ; Financial Interests, Personal, Other, Company-sponsored trials at institution (PI roles): AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Nuvalent, Pfizer, Phosplatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20